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LETTERS TO THE EDITORS 
The Editors invite readers to submit letters commenting on the contents of articles 
that appear in the JOURNAL. Also welcome are brief communications in letter form 
reporting investigative or clinical observations without extensive documentation 
and with brief bibliography (five titles or less), not requiring peer review but open 
to critique by readers. Letters to the Editors should be no more than 500 words 
in length and they may have to be edited for publication. 
Re: "Thrombolysis with tissue-plasminogen activator: 
Results with a high-dose transthrombus technique" 
To the Editors: 
We read with interest the article by Ward et al. (J VAse 
SuwG 1994;19:503-8). Their clinical failure rate (52%) and 
major hemorrhage rate (35%) are indeed excessive, and it 
is understandable that they are reevaluating their use of 
thrombolysis with tissue-type plasminogen activator 
(t-VA). 
The Thrombolysis Study Group, a group of 19 
surgeons and 14 radiologists in the United Kingdom, has 
recently built a database of information on peripheral 
thrombolysis. Data are collected prospectively on record 
forms and are entered onto a specially designed computer 
program from which reports on the group's results are 
generated. In the last 12 months 73 patients have been 
treated with an initial high-dose bolus oft-PA. The patients 
treated by the group were similar to those of Ward et al., 
with a 50:50 split in sexes, a mean age of 68 years (range 
19 to 90 years), a mean duration of ischemia of 14 days 
(range 0 to 150 days), and a similar distribution ofischemia 
(17% Fontaine II and 73% Fontaine III). Boluses oft-PA 
ranged from 3 mg to 20 mg for 15 to 30 minutes. These 
boluses were followed by infusions of 0.5 to 3.5 mg/hr for 
up to 4 hours and then, if required, low-dose infusions (0.5 
to I mg/hr). Additional procedures uch as aspiration 
embolectomy, angioplasty, or graft reconstruction were 
required in 62 (85%) patients, 
Seventy-two percent of patients had successful throm- 
bolysis with a mean duration of infusion of 12 hours (range 
0.5 to 27 hours). The limb salvage rate on the thirtieth day 
after treatment was 71% (52 patients). Our amputation 
and death rates were 10% and 19%, respectively. Most 
important he major hemorrhage rate was 11% (eight 
patients, ix at the site of cannulation and two strokes). This 
rate is vastly different from the 35% hemorrhagic compli- 
cation rate in the article by Ward et al. 
Our results in more than three times as many patients 
were reported from 10 centers in the United Kingdom and 
contradict those of the article by Ward et al. Bolus therapy 
with t-PA was significantly faster than low-dose infusion 
and was associated with similar efficacy and complications 
in our patients. The article by Ward et al. is based on a small 
number of patients, and their conclusions should be viewed 
in this light. To establish the role of high-dose bolus t-PA 
540 
thrombolysis n the management of acute limb ischemia, 
we should await the results of the randomized trial of 
high-dose and low-dose infusions of t-PA that is currently 
in progress by our group. 
B. D. Braithwaite, M_A, FRCS, 
The Thrombolysis Study Group* 
Gloucestershire Royal Hospital 
Great Western Road 
Gloucester GL1 3NN 
United Kingdom 
*Members of the TSG contributing to the results in this letter 
include Dr. A. A1-Kutoubi, Mr. J. Beard, Mr. D.C. Berridge, Dr. 
P. A. Birch, Dr. T. Buckenham, Mr. K. Dawson, Mr. 1. 
Dormandy, Mr. J. J. Earnshaw, Dr. P. A. Gaines, Mr. R. B, 
Galland, Mr. B. P. Heather, Mr. G. Hamilton, Dr. L. Jones, Dr. 
A. Platts, Dr. P. Torrie, Mr. J. Wolfe. 
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Regarding "The incidence of deep venous thrombosis  
in patients undergoing abdominal aortic 
aneurysm resection" 
To the Editors: 
The recent article, "The incidence of deep venous 
thrombosis in patients undergoing abdominal aortic aneu- 
rysm resection," by Olin et al. (J VAse SURG 1993; 18:1037- 
41) addresses the very important issue of patients undergo- 
ing an aortic surgical procedure and whether they have a 
high incidence of deep vein thrombosis. It also brings up 
the very controversial point about whether prophylaxis i
necessary in this group of patients. The authors refer to the 
paucity of data in the literature assessing the incidence of 
deep vein thrombosis (DVT) after an aortic surgical proce- 
dure with iodine 125-labeled fibrinogen leg scanning used 
as the primary method of diagnosis of DVT. 
I would like to suggest that the article written by Byrne 
et al. (Surg Gynecol Obstet 1984;158:419-22) addresses 
this issue quite clearly. We looked at 28 patients who all had 
aortic reconstruction, either aneurysm or aortobifemoral 
bypass. We detected only a 7.1% incidence of DVT in this 
group of patients, and we believcd that an intravenous 
administration of 5000 U heparin during the procedure 
acted as a prophylaxis against he development of DVT. 
